SCHEMBL2590514

SCHEMBL2590514

OCc1ccc2nc(-c3cccs3)oc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.53
▸ MAPT P10636 2/20 0.53
▸ HSD17B10 Q99714 2/20 0.53
▸ TP53 P04637 2/20 0.53
▸ RAB9A P51151 2/20 0.53
▸ NPC1 O15118 1/20 0.53
▸ GFER P55789 1/20 0.53
▸ GPR119 Q8TDV5 7/20 0.51
▸ ALDH1A1 P00352 4/20 0.46
▸ HPGD P15428 4/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ SYK P43405 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ F2 P00734 1/20 0.45
▸ GAA P10253 1/20 0.43
▸ MAPK1 P28482 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5760665 0.89 KDM4E (0.64) KDM4EMAPTHSD17B10TP53RAB9A
SCHEMBL10611894 0.82 GPR119 (0.51) KDM4EMAPTHSD17B10TP53RAB9A
SCHEMBL25027923 0.80 KDM4E (0.71) KDM4EMAPTHSD17B10TP53RAB9A
SCHEMBL12501435 0.78 KDM4E (0.78) KDM4EMAPTHSD17B10TP53RAB9A
SCHEMBL3096924 0.77 SMN1; SMN2 (0.54) KDM4EMAPTHSD17B10TP53RAB9A
SCHEMBL26745312 0.76 KDM4E (0.70) KDM4EMAPTHSD17B10TP53RAB9A
SCHEMBL27829133 0.76 KDM4E (0.65) KDM4EMAPTHSD17B10TP53RAB9A
SCHEMBL1129179 0.76 KDM4E (0.65) KDM4EMAPTHSD17B10TP53RAB9A
SCHEMBL2586944 0.75 GPR119 (0.54) KDM4EMAPTHSD17B10TP53RAB9A
SCHEMBL5760346 0.75 KDM4E (0.64) KDM4EMAPTHSD17B10TP53RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2566864-B1 PYRIDAZINONES AS GPR119 AGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-09-03 — — EP disclosed
US-8772323-B2 Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-08 — — US disclosed
US-20130172323-A1 PYRIDAZINONES AS GPR119 AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-07-04 — — US disclosed
EP-2566864-A2 PYRIDAZINONES AS GPR119 AGONISTS Boehringer Ingelheim International GmbH (DE) 2013-03-13 — — EP disclosed
WO-2011138427-A2 PYRIDAZINONES AS GPR119 AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172323-A1 PYRIDAZINONES AS GPR119 AGONISTS GPR65, GPR119, GPR55 KDM4E 3665/4885MAPT 2190/4885HSD17B10 1430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback